Cresemba / Isavuconazole:  Not Just Another Azole

It is amazing how modifications to the azole structure have produced ever more potent, ever more useful antifungals.  Ketoconazole had limited usability because of its many side effects related to off-target sterol synthesis inhibition, solubility (or lack thereof) and erratic absorption.  Solublity was also an issue for itraconazole and posaconazole.  Continue reading Cresemba / Isavuconazole:  Not Just Another Azole

Drugs with QIDP Designation – Update 4/8/2015

For the latest QIDP listing, please click HERE Our latest internet search came up with 37 drugs that garnered QIDP status.  They are listed in the Table below (if I missed a compound, please leave a comment!!).  The table is searchable so you should be able to massage the data to Continue reading Drugs with QIDP Designation – Update 4/8/2015

Aerosolized Antibiotics & Selling Nebulizers

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent antibiotics. The inhalational route to administer antibiotics is clearly attractive.  Continue reading Aerosolized Antibiotics & Selling Nebulizers